Krystal Biotech (KRYS) Up 3.3% Since Last Earnings Report: Can It Continue?

It has been about a month since the last earnings report for Krystal Biotech, Inc. (KRYS). Shares have added about 3.3% in that time frame, outperforming the S&P 500.Will the recent positive trend continue leading up to its next earnings release, or is Krystal Biotech due for a pullback? Before we dive into how investors and analysts have reacted as of late, let's take a quick look at its most recent earnings report in order to get a better handle on the important catalysts.How Have Estimates Been Moving Since Then?It turns out, fresh estimates have trended upward during the past month.The consensus estimate has shifted 11% due to these changes.VGM ScoresCurrently, Krystal Biotech has a great Growth Score of A, though it is lagging a lot on the Momentum Score front with an F. Charting a somewhat similar path, the stock was allocated a grade of D on the value side, putting it in the bottom 40% for this investment strategy.Overall, the stock has an aggregate VGM Score of C. If you aren't focused on one strategy, this score is the one you should be interested in.OutlookEstimates have been trending upward for the stock, and the magnitude of this revision looks promising. It comes with little surprise Krystal Biotech has a Zacks Rank #2 (Buy). We expect an above average return from the stock in the next few months.Performance of an Industry PlayerKrystal Biotech belongs to the Zacks Medical - Biomedical and Genetics industry. Another stock from the same industry, Astrazeneca (AZN), has gained 2.6% over the past month. More than a month has passed since the company reported results for the quarter ended December 2024.Astrazeneca reported revenues of $14.89 billion in the last reported quarter, representing a year-over-year change of +23.8%. EPS of $1.05 for the same period compares with $0.73 a year ago.For the current quarter, Astrazeneca is expected to post earnings of $1.10 per share, indicating a change of +6.8% from the year-ago quarter. The Zacks Consensus Estimate has changed +1% over the last 30 days.The overall direction and magnitude of estimate revisions translate into a Zacks Rank #4 (Sell) for Astrazeneca. Also, the stock has a VGM Score of C.Only $1 to See All Zacks' Buys and SellsWe're not kidding.Several years ago, we shocked our members by offering them 30-day access to all our picks for the total sum of only $1. No obligation to spend another cent.Thousands have taken advantage of this opportunity. Thousands did not - they thought there must be a catch. Yes, we do have a reason. We want you to get acquainted with our portfolio services like Surprise Trader, Stocks Under $10, Technology Innovators,and more, that closed 256 positions with double- and triple-digit gains in 2024 alone.See Stocks Now >>Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Krystal Biotech, Inc. (KRYS): Free Stock Analysis Report AstraZeneca PLC (AZN): Free Stock Analysis ReportThis article originally published on Zacks Investment Research (zacks.com).Zacks Investment ResearchWeiter zum vollständigen Artikel bei Zacks Weiter zum vollständigen Artikel bei Zacks